As a chemoattractant for myeloid-derived suppressor cells (MDSCs), by which it is also actively secreted, CXCL2 inhibits the expansion and activity of anti-tumor immune cells, such as T and NK cells [51,52] and partakes in cancer metastasis by preparing metastatic niche, escorting circulating tumor cells, and enabling their extravasation [52]. Here, CXCL2 is linked to cancer.